Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A414BN | ISIN: US47010C8881 | Ticker-Symbol: 1JA0
NASDAQ
25.06.25 | 21:42
2,940 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJaguar Health seeks EU approval for dog diarrhea treatment9
MiJaguar Health, Inc.: Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs136Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possibility...
► Artikel lesen
DiJaguar Health verlängert Fälligkeitsdatum für Schuldverschreibungen im Wert von 2,57 Millionen US-Dollar7
DiJaguar Health, Inc.: Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026901Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24...
► Artikel lesen
MoJaguar Health, Inc.: Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer150Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately...
► Artikel lesen
FrJaguar Health files to sell 507.4K shares of common stock by selling shareholders3
JAGUAR HEALTH Aktie jetzt für 0€ handeln
17.06.Jaguar Health, Inc.: Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts174Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present...
► Artikel lesen
11.06.Jaguar Health, Inc.: First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs308Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer...
► Artikel lesen
09.06.Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series614Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted...
► Artikel lesen
09.06.Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer3
09.06.Jaguar Health, Inc.: Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer189Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving...
► Artikel lesen
22.05.Jaguar Health, Inc. - 8-K, Current Report20
21.05.Jaguar Health Stock Falls 23% Following $1.5 Mln Direct Offering Announcement4
21.05.Jaguar Health kündigt Direktplatzierung in Höhe von 1,5 Millionen US-Dollar an24
21.05.Jaguar Health announces $1.5 million direct offering2
21.05.Jaguar Health, Inc.: Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules225SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and...
► Artikel lesen
20.05.Jaguar Health, Inc.: First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease270As announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient...
► Artikel lesen
19.05.Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Initiation of Coverage Recommendation - Buy416Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH 19.05.2025 / 16:37 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
16.05.Jaguar Health outlines rare disease catalyst convergence and expedited regulatory pathways for crofelemer following proof-of-concept results6
15.05.Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 Financials405The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4...
► Artikel lesen
Weiter >>
122 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1